CDK2 inhibition disorders centrosome stoichiometry and alters cellular outcomes in aneuploid cancer cells

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–17. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Nigg EA. Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer. 2002;2(1):815–825. doi:10.1038/nrc924.
   PubMedGoogle Scholar
• Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature. 2009;460(7252):278–282. doi:10.1038/nature08136.
   PubMed Web of Science ®Google Scholar
• Pihan GA. Centrosome dysfunction contributes to chromosome instability, chromoanagenesis, and genomic reprogramming in cancer. Front Oncol. 2013;3(277):1–26. doi:10.3389/fonc.2013.00277.
   PubMedGoogle Scholar
• Godinho SA, Pellman D. Causes and consequences of centrosome abnormalities in cancer. Philos Trans R Soc Lond B Biol Sci. 2014;369(1650):1–13. doi:10.1098/rstb.2013.0467.
   Web of Science ®Google Scholar
• Rajagopalan H, Lengauer C. Aneuploidy and cancer. Nature. 2004;432(7015):338–341. doi:10.1038/nature03099.
   PubMed Web of Science ®Google Scholar
• Gao C, Furge K, Koeman J, Dykema K, Su Y, Cutler ML, Werts A, Haak P, Vande Woude GF. Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proc Natl Acad Sci U S A. 2007;104(21):8995–9000. doi:10.1073/pnas.0700631104.
   PubMed Web of Science ®Google Scholar
• Silkworth WT, Nardi IK, Scholl LM, Cimini D, Hardwick KG. Multipolar spindle pole coalescence is a major source of kinetochore mis-attachment and chromosome mis-segregation in cancer cells. PloS One. 2009;4(8):e6564. doi:10.1371/journal.pone.0006564.
   PubMed Web of Science ®Google Scholar
• Chan JY. A clinical overview of centrosome amplification in human cancers. Int J Biol Sci. 2011;7(8):1122–1144. doi:10.7150/ijbs.7.1122.
   PubMed Web of Science ®Google Scholar
• Bettencourt-Dias M, Glover DM. Centrosome biogenesis and function: centrosomics brings new understanding. Nat Rev Mol Cell Biol. 2007;8(6):451–463. doi:10.1038/nrm2180.
   PubMed Web of Science ®Google Scholar
• Nigg EA. Centrosome duplication: of rules and licenses. Trends Cell Biol. 2007;17(5):215–221. doi:10.1016/j.tcb.2007.03.003.
   PubMed Web of Science ®Google Scholar
• Nigg EA, Holland AJ. Once and only once: mechanisms of centriole duplication and their deregulation in disease. Nat Rev Mol Cell Biol. 2018;19(5):297–312. doi:10.1038/nrm.2017.127.
   PubMed Web of Science ®Google Scholar
• Fukasawa K. Oncogenes and tumour suppressors take on centrosomes. Nat Rev Cancer. 2007;7(12):911–924. doi:10.1038/nrc2249.
   PubMed Web of Science ®Google Scholar
• Hinchcliffe EH, Sluder G. “It takes two to tango”: understanding how centrosome duplication is regulated throughout the cell cycle. Genes Dev. 2001;15(10):1167–1181. doi:10.1101/gad.894001.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Maller JL. A centrosomal localization signal in cyclin E required for Cdk2-independent S phase entry. Sci. 2004;306(5697):885–888. doi:10.1126/science.1103544.
   PubMed Web of Science ®Google Scholar
• Arquint C, Cubizolles F, Morand A, Schmidt A, Nigg EA. The SKP1-cullin-F-box E3 ligase betaTrcp and CDK2 cooperate to control STIL abundance and centriole number. Open Biol. 2018;8(2):170253. doi:10.1098/rsob.170253.
   PubMed Web of Science ®Google Scholar
• Kasbek C, Yang C-H, Yusof AM, Chapman HM, Winey M, Fisk HA. Preventing the degradation of mps1 at centrosomes is sufficient to cause centrosome reduplication in human cells. Mol Biol Cell. 2007;18(11):4457–4469. doi:10.1091/mbc.e07-03-0283.
   PubMed Web of Science ®Google Scholar
• Ferguson RL, Maller JL. Centrosomal localization of cyclin E-Cdk2 is required for initiation of DNA synthesis. Curr Biol. 2010;20(9):856–860. doi:10.1016/j.cub.2010.03.028.
   PubMed Web of Science ®Google Scholar
• Duensing S. Analysis of centrosomes in human cancer. Methods Cell Biol. 2015;129(51):51–60. doi:10.1016/bs.mcb.2015.03.002.
   PubMedGoogle Scholar
• Hinchcliffe EH, Li C, Thompson EA, Maller JL, Sluder G. Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in xenopus egg extracts. Sci. 1999;283(5403):851–854. doi:10.1126/science.283.5403.851.
   PubMed Web of Science ®Google Scholar
• Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan P-K, Knudsen ES, Hofmann IA, Snyder JD, Bove KE, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell. 2000;103(1):127–140. doi:10.1016/s0092-8674(00)00093-3.
   PubMed Web of Science ®Google Scholar
• Tokuyama Y, Horn HF, Kawamura K, Tarapore P, Fukasawa K. Specific phosphorylation of nucleophosmin on Thr(199) by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication. J Biol Chem. 2001;276(24):21529–21537. doi:10.1074/jbc.M100014200.
   PubMed Web of Science ®Google Scholar
• Adon AM, Zeng X, Harrison MK, Sannem S, Kiyokawa H, Kaldis P, Saavedra HI. Cdk2 and Cdk4 regulate the centrosome cycle and are critical mediators of centrosome amplification in p53-null cells. Mol Cell Biol. 2010;30(3):694–710. doi:10.1128/MCB.00253-09.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Hayashi K, Nishida E. Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells. Curr Biol. 1999;9(8):429–432. doi:10.1016/s0960-9822(99)80191-2.
   PubMed Web of Science ®Google Scholar
• Meraldi P, Lukas J, Fry AM, Bartek J, Nigg EA. Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin a. Nat Cell Biol. 1999;1(2):88–93. doi:10.1038/10054.
   PubMed Web of Science ®Google Scholar
• Tsou M-F, Stearns T. Mechanism limiting centrosome duplication to once per cell cycle. Nature. 2006;442(7105):947–951. doi:10.1038/nature04985.
   PubMed Web of Science ®Google Scholar
• Duensing A, Liu Y, Tseng M, Malumbres M, Barbacid M, Duensing S. Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication. Oncogene. 2006;25(20):2943–2949. doi:10.1038/sj.onc.1209310.
   PubMed Web of Science ®Google Scholar
• Saavedra HI, Maiti B, Timmers C, Altura R, Tokuyama Y, Fukasawa K, Leone G. Inactivation of E2F3 results in centrosome amplification. Cancer Cell. 2003;3(4):333–346. doi:10.1016/s1535-6108(03)00083-7.
   PubMed Web of Science ®Google Scholar
• Jusino S, Fernandez-Padin FM, Saavedra HI. Centrosome aberrations and chromosome instability contribute to tumorigenesis and intra-tumor heterogeneity. J Cancer Metastasis Treat. 2018;4(8):43. doi:10.20517/2394-4722.2018.24.
   PubMedGoogle Scholar
• Schneeweiss A, Sinn H-P, Ehemann V, Khbeis T, Neben K, Krause U, Ho AD, Bastert G, Krämer A. Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression. Int J Cancer. 2003;107(3):346–352. doi:10.1002/ijc.11408.
   PubMed Web of Science ®Google Scholar
• Pannu V, Mittal K, Cantuaria G, Reid MD, Li X, Donthamsetty S, McBride M, Klimov S, Osan R, Gupta MV, et al. Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers. Oncotarget. 2015;6(12):10487–10497. doi:10.18632/oncotarget.3402.
   PubMedGoogle Scholar
• Levine MS, Bakker B, Boeckx B, Moyett J, Lu J, Vitre B, Spierings DC, Lansdorp PM, Cleveland DW, Lambrechts D, et al. Centrosome amplification is sufficient to promote spontaneous tumorigenesis in mammals. Dev Cell. 2017;40(3):313–322 e5. doi:10.1016/j.devcel.2016.12.022.
   PubMed Web of Science ®Google Scholar
• Godinho SA, Picone R, Burute M, Dagher R, Su Y, Leung CT, Polyak K, Brugge JS, Théry M, Pellman D. Oncogene-like induction of cellular invasion from centrosome amplification. Nature. 2014;7503510(7503):167–171. doi:10.1038/nature13277.
   Google Scholar
• Lee M, Oprea-Ilies G, Saavedra HI. Silencing of E2F3 suppresses tumor growth of Her2+ breast cancer cells by restricting mitosis. Oncotarget. 2015;6(35):37316–37334. doi:10.18632/oncotarget.5686.
   PubMedGoogle Scholar
• Kawakami M, Liu X, Dmitrovsky E. New cell cycle inhibitors target aneuploidy in cancer therapy. Annu Rev Pharmacol Toxicol. 2019;59(1):361–377. doi:10.1146/annurev-pharmtox-010818-021649.
   PubMedGoogle Scholar
• Rivera-Rivera Y, Saavedra HI. Centrosome - a promising anti-cancer target. Biologics. 2016;10:167–176. doi:10.2147/BTT.S87396.
   PubMedGoogle Scholar
• Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, et al. Palbociclib and Letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936. doi:10.1056/NEJMoa1607303.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748. doi:10.1056/NEJMoa1609709.
   PubMed Web of Science ®Google Scholar
• Kawakami M, Mustachio LM, Zheng L, Chen Y, Rodriguez-Canales J, Mino B, Kurie JM, Roszik J, Villalobos PA, Thu KL, et al. Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers. Proc Natl Acad Sci U S A. 2018;115(8):1913–1918. doi:10.1073/pnas.1719760115.
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Fenaux P, Craig MD, Gyan E, Lister J, Kassis J, Pigneux A, Schiller GJ, Jung J, Jane Leonard E, et al. An exploratory phase 2 study of investigational aurora a kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes. Leuk Res Rep. 2014;3(2):58–61. doi:10.1016/j.lrr.2014.06.003.
   PubMedGoogle Scholar
• Chen JA, Huynh JC, Wu CY, Yu A-M, Matsukuma K, Semrad TJ, Gandara DR, Li T, Riess JW, Tam K, et al. A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer. Cancer Chemother Pharmacol. 2022;90(3):217–228. doi:10.1007/s00280-022-04457-9.
   PubMed Web of Science ®Google Scholar
• Zheng L, Chen Z, Kawakami M, Chen Y, Roszik J, Mustachio LM, Kurie JM, Villalobos P, Lu W, Behrens C et al. Tyrosine threonine kinase inhibition eliminates lung cancers by augmenting apoptosis and polyploidy. Mol Cancer Ther. 2019;18(10):1775–1786. doi:10.1158/1535-7163.MCT-18-0864.
   PubMed Web of Science ®Google Scholar
• Mason JM, Wei X, Fletcher GC, Kiarash R, Brokx R, Hodgson R, Beletskaya I, Bray MR, Mak TW. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad. Sci U S A. 2017;114(12):3127–3132. doi:10.1073/pnas.1700234114.
   PubMed Web of Science ®Google Scholar
• Galimberti F, Thompson SL, Liu X, Li H, Memoli V, Green SR, DiRenzo J, Greninger P, Sharma SV, Settleman J, et al. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res. 2010;16(1):109–120. doi:10.1158/1078-0432.CCR-09-2151.
   PubMed Web of Science ®Google Scholar
• Galimberti F, Thompson SL, Ravi S, Compton DA, Dmitrovsky E. Anaphase catastrophe is a target for cancer therapy. Clin Cancer Res. 2011;17(6):1218–1222. doi:10.1158/1078-0432.CCR-10-1178.
   PubMed Web of Science ®Google Scholar
• Hu S, Danilov AV, Godek K, Orr B, Tafe LJ, Rodriguez-Canales J, Behrens C, Mino B, Moran CA, Memoli VA, et al. CDK2 inhibition causes anaphase catastrophe in lung cancer through the centrosomal protein CP110. Cancer Res. 2015;75(10):2029–2038. doi:10.1158/0008-5472.CAN-14-1494.
   PubMed Web of Science ®Google Scholar
• Hu S, Lu Y, Orr B, Godek K, Mustachio LM, Kawakami M, Sekula D, Compton DA, Freemantle S, Dmitrovsky E, et al. Specific CP110 phosphorylation sites mediate anaphase catastrophe after CDK2 inhibition: evidence for cooperation with USP33 knockdown. Mol Cancer Ther. 2015;14(11):2576–2585. doi:10.1158/1535-7163.MCT-15-0443.
   PubMed Web of Science ®Google Scholar
• Kawakami M, Mustachio LM, Chen Y, Chen Z, Liu X, Wei C-H, Roszik J, Kittai AS, Danilov AV, Zhang X, et al. A novel CDK2/9 inhibitor CYC065 causes anaphase catastrophe and represses proliferation, tumorigenesis, and metastasis in aneuploid cancers. Mol Cancer Ther. 2021;20(3):477–489. doi:10.1158/1535-7163.MCT-19-0987.
   PubMed Web of Science ®Google Scholar
• Kawakami M, Mustachio LM, Rodriguez-Canales J, Mino B, Roszik J, Tong P, Wang J, Lee JJ, Myung JH, Heymach JV, et al. Next-generation CDK2/9 inhibitors and anaphase catastrophe in lung cancer. J Natl Cancer Inst. 2017;109(6):djw29. doi:10.1093/jnci/djw297.
   Google Scholar
• Danilov AV, Hu S, Orr B, Godek K, Mustachio LM, Sekula D, Liu X, Kawakami M, Johnson FM, Compton DA, et al. Dinaciclib induces anaphase catastrophe in lung cancer cells via inhibition of cyclin-dependent kinases 1 and 2. Mol Cancer Ther. 2016;15(11):2758–2766. doi:10.1158/1535-7163.MCT-16-0127.
   PubMed Web of Science ®Google Scholar
• Magidson V, O’Connell C, Lončarek J, Paul R, Mogilner A, Khodjakov A. The spatial arrangement of chromosomes during prometaphase facilitates spindle assembly. Cell. 2011;146(4):555–567. doi:10.1016/j.cell.2011.07.012.
   PubMed Web of Science ®Google Scholar
• Narayan K, Subramaniam S. Focused ion beams in biology. Nat Methods. 2015;12(11):1021–1031. doi:10.1038/nmeth.3623.
   PubMed Web of Science ®Google Scholar
• Narayan K, Danielson CM, Lagarec K, Lowekamp BC, Coffman P, Laquerre A, Phaneuf MW, Hope TJ, Subramaniam S. Multi-resolution correlative focused ion beam scanning electron microscopy: applications to cell biology. J Struct Biol. 2014;185(3):278–284. doi:10.1016/j.jsb.2013.11.008.
   PubMed Web of Science ®Google Scholar
• Ma Y, Fiering S, Black C, Liu X, Yuan Z, Memoli VA, Robbins DJ, Bentley HA, Tsongalis GJ, Demidenko E, et al. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci USA. 2007;20074(1010):4089–4094. doi:10.1073/pnas.0606537104.
   Google Scholar
• Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest. 2010;120(4):1298–1309. doi:10.1172/JCI39566.
   PubMed Web of Science ®Google Scholar
• Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, Langley RR, Tang H, Burdick MD, Sato M, Minna JD, et al. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res. 2006;66(8):4198–4207. doi:10.1158/0008-5472.CAN-05-3842.
   PubMed Web of Science ®Google Scholar
• Chen Z, Zheng L, Chen Y, Liu X, Kawakami M, Mustachio LM, Roszik J, Ferry-Galow KV, Parchment RE, Liu X, et al. Loss of ubiquitin-specific peptidase 18 destabilizes 14-3-3ζ protein and represses lung cancer metastasis. Cancer Biol Ther. 2022;23(1):265–280. doi:10.1080/15384047.2022.2054242.
   PubMed Web of Science ®Google Scholar
• Baena V, Terasaki M. Three-dimensional organization of transzonal projections and other cytoplasmic extensions in the mouse ovarian follicle. Sci Rep. 2019;9(1):1262. doi:10.1038/s41598-018-37766-2.
   PubMedGoogle Scholar